222 related articles for article (PubMed ID: 27255487)
21. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
22. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database.
Hunt CM; Yuen NA; Stirnadel-Farrant HA; Suzuki A
Regul Toxicol Pharmacol; 2014 Nov; 70(2):519-26. PubMed ID: 25236535
[TBL] [Abstract][Full Text] [Related]
23. Drugs associated with adverse events in children and adolescents.
Lee WJ; Lee TA; Pickard AS; Caskey RN; Schumock GT
Pharmacotherapy; 2014 Sep; 34(9):918-26. PubMed ID: 24990656
[TBL] [Abstract][Full Text] [Related]
24. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
[TBL] [Abstract][Full Text] [Related]
25. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China.
Hou Y; Ye X; Wu G; Cheng G; Du X; He J
Expert Opin Drug Saf; 2014 Jul; 13(7):853-7. PubMed ID: 24918197
[TBL] [Abstract][Full Text] [Related]
26. A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands.
Scholl JHG; van Hunsel FPAM; Hak E; van Puijenbroek EP
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):199-205. PubMed ID: 29271017
[TBL] [Abstract][Full Text] [Related]
27. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database.
Yang H; Wan Z; Chen M; Zhang X; Cui W; Zhao B
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):217-223. PubMed ID: 37243615
[TBL] [Abstract][Full Text] [Related]
28. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.
Arabyat RM; Raisch DW; McKoy JM; Bennett CL
Expert Opin Drug Saf; 2015; 14(11):1653-60. PubMed ID: 26393387
[TBL] [Abstract][Full Text] [Related]
29. Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems.
Osokogu OU; Fregonese F; Ferrajolo C; Verhamme K; de Bie S; 't Jong G; Catapano M; Weibel D; Kaguelidou F; Bramer WM; Hsia Y; Wong IC; Gazarian M; Bonhoeffer J; Sturkenboom M
Drug Saf; 2015 Feb; 38(2):207-17. PubMed ID: 25663078
[TBL] [Abstract][Full Text] [Related]
30. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
[TBL] [Abstract][Full Text] [Related]
31. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
[TBL] [Abstract][Full Text] [Related]
32. Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.
Antonazzo IC; Raschi E; Forcesi E; Riise T; Bjornevik K; Baldin E; De Ponti F; Poluzzi E
Expert Opin Drug Saf; 2018 Sep; 17(9):869-874. PubMed ID: 30058390
[TBL] [Abstract][Full Text] [Related]
33. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
Hauben M; Reich L; Chung S
Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010-2020: A Cross-Sectional Study.
Phan M; Cheng C; Dang V; Wu E; Muñoz MA
Ther Innov Regul Sci; 2023 Sep; 57(5):1062-1073. PubMed ID: 37351842
[TBL] [Abstract][Full Text] [Related]
35. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Alatawi YM; Hansen RA
Expert Opin Drug Saf; 2017 Jul; 16(7):761-767. PubMed ID: 28447485
[TBL] [Abstract][Full Text] [Related]
36. A stratification method based on clustering for the minimization of data masking effect in signal detection.
Wei JX; Ding Y; Li M; Sun J
BMC Med Inform Decis Mak; 2020 Feb; 20(1):18. PubMed ID: 32013983
[TBL] [Abstract][Full Text] [Related]
37. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System.
Serebruany VL; Hall TS; Atar D; Agewall S; Hyun Kim M; Geudelin B; Lomakin N; Marciniak TA
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):210-215. PubMed ID: 30192939
[TBL] [Abstract][Full Text] [Related]
38. A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases.
Arnaud M; Salvo F; Ahmed I; Robinson P; Moore N; Bégaud B; Tubert-Bitter P; Pariente A
Drug Saf; 2016 Mar; 39(3):251-60. PubMed ID: 26715499
[TBL] [Abstract][Full Text] [Related]
39. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
Setyawan J; Azimi N; Strand V; Yarur A; Fridman M
Drug Saf; 2021 Aug; 44(8):889-897. PubMed ID: 34120321
[TBL] [Abstract][Full Text] [Related]
40. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
